地西他滨联合MAE方案治疗急性髓系白血病效果及对血清TK1和IL-6及Hepc水平影响  

Effect of MAE regimen with combined decitabine in treatment of leukemia myeloid acute and its influence on serum TK1 and IL-6 and Hepc levels

作　　者：刘芳[1] 杨瑞峥 杨爽 LIU Fang;YANG Rui-Zheng;YANG Shuang(Department of Hematology Ward 1,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 453400,China)

机构地区：[1]郑州大学第一附属医院血液科一病区,郑州453400

出　　处：《医药论坛杂志》2025年第2期198-202,共5页Journal of Medical Forum

摘　　要：目的 研究急性髓系白血病患者采用地西他滨联合MAE方案(米托蒽醌+阿糖胞苷)治疗的效果及治疗前后血清胸苷激酶(thymidine kinase 1,TK1)、白细胞介素—6(interleukin-6,IL-6)和铁调素(hepcidin,Hepc)水平的变化。方法 选取郑州大学第一附属医院2021年2月—2023年1月收治的急性髓系白血病92例,将采用MAE方案治疗的46例作为对照组,采用地西他滨联合MAE方案治疗的46例作为研究组。回顾性比较两组临床疗效、治疗前后血管生成调控因子[碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF)、血管内皮生长因子(vascular endothelial growth factor,VEGF)]水平、血清TK1、IL-6、白细胞介素-22(interleukin-22,IL-22)、Hepc水平、卡式评分(Karnofsky performance status,KPS)及不良反应。结果 研究组总有效率82.61%,高于对照组63.04%,差异有统计学意义(P<0.05);两组治疗前bFGF及VEGF水平比较,差异无统计学意义(P>0.05),治疗28 d后均降低,且研究组血清bFGF及VEGF水平为(15.69±3.68)IU/mg及(53.64±6.79)pg/mL,均低于对照组,差异有统计学意义(P<0.05);研究组治疗后28 d血清TK1、IL-6、IL-22、Hepc水平分别是(2.75±0.63)pmol/L、(22.68±4.52)ng/L、(19.85±3.14)ng/L及(191.02±21.63)ng/mL,均低于对照组,差异有统计学意义(P<0.05);两组治疗28 d后KPS评分均升高,且研究组(85.46±4.12)分,高于对照组(77.35±5.39)分,差异有统计学意义(P<0.05);不良反应总发生率方面,研究组18.60%与对照组11.63%比较,差异无统计学意义(P>0.05)。结论 地西他滨联合MAE方案治疗急性髓系白血病疗效确切,抑制病情发展,改善机体状况,且安全性较高。Objective To study the effect of decitabine combined with MAE regimen(mitoxantrone + cytarabine)in the treatment of acute myeloid leukemia and the changes of serum thymidine kinase(TK1),interleukin-6(IL-6)and hepcidin(Hepc)levels before and after treatment.Methods Totally 92 patients with acute myeloid leukemia admitted to the First Affiliated Hospital of Zhengzhou University from February 2021 to January 2023 into control group and study group with 46 cases in each group.The MAE regimen treated with control group,and decitabine combined with MAE regimen treated with study group.The clinical efficacy,levels of angiogenesis regulatory factors basic fibroblast growth factor(bFGF),vascular endothelial growth factor(VEGF),serum TK1,IL-6,interleukin-22(IL-22),Hepc level,after treatment and between the two groups before,compared Karnofsky performance status(KPS) score and incidence of were reactions adverse.Results After 28 days of treatment,the total effective rate of the group study was 82.61%,higher than that of the control group(63.04%),and the difference was statistically significant(P<0.05).The levels of bFGF and VEGF in the two groups before treatment were decreased,and the difference were not statistically significant(P>0.05),and the serum levels of bFGF and VEGF in the study group were(15.69±3.68) IU/mg and(53.64±6.79) pg/mL,which lower than those in the control group,and the difference were statistically significant(P<0.05).The levels of serum TK1,IL-6,IL-22 and Hepc in the 2 groups before treatment were decreased after 28 days of treatment,and the difference were not statistically significant(P>0.05).The serum levels of TK1,IL-6,IL-22 and Hepc in the study group after 28 days of treatment were(2.75±0.63) pmol/L,(22.68±4.52) ng/L,(19.85±3.14) ng/L and(191.02±21.63) ng/mL,respectively,which were lower than those in the control group(P<0.05).After 28 days of treatment,the KPS scores of the two groups increased,and the KPS scores of the study group(85.46±4.12)were higher than those of the control group(77

关 键 词：地西他滨 MAE方案 急性髓系白血病 疗效 

分 类 号：R733.71[医药卫生—肿瘤]